JP2017525776A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525776A5
JP2017525776A5 JP2017530425A JP2017530425A JP2017525776A5 JP 2017525776 A5 JP2017525776 A5 JP 2017525776A5 JP 2017530425 A JP2017530425 A JP 2017530425A JP 2017530425 A JP2017530425 A JP 2017530425A JP 2017525776 A5 JP2017525776 A5 JP 2017525776A5
Authority
JP
Japan
Prior art keywords
disorder
disease
dementia
pharmaceutical composition
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017530425A
Other languages
English (en)
Japanese (ja)
Other versions
JP6430015B2 (ja
JP2017525776A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/069601 external-priority patent/WO2016030444A1/en
Publication of JP2017525776A publication Critical patent/JP2017525776A/ja
Publication of JP2017525776A5 publication Critical patent/JP2017525776A5/ja
Application granted granted Critical
Publication of JP6430015B2 publication Critical patent/JP6430015B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017530425A 2014-08-27 2015-08-27 新規クロモンオキシム誘導体、および代謝型グルタミン酸受容体のアロステリックモジュレーターとしてのそれの使用 Expired - Fee Related JP6430015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182468 2014-08-27
EP14182468.0 2014-08-27
PCT/EP2015/069601 WO2016030444A1 (en) 2014-08-27 2015-08-27 Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

Publications (3)

Publication Number Publication Date
JP2017525776A JP2017525776A (ja) 2017-09-07
JP2017525776A5 true JP2017525776A5 (enExample) 2017-10-19
JP6430015B2 JP6430015B2 (ja) 2018-11-28

Family

ID=51421865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017530425A Expired - Fee Related JP6430015B2 (ja) 2014-08-27 2015-08-27 新規クロモンオキシム誘導体、および代謝型グルタミン酸受容体のアロステリックモジュレーターとしてのそれの使用

Country Status (26)

Country Link
US (3) US10017521B2 (enExample)
EP (3) EP3186257B1 (enExample)
JP (1) JP6430015B2 (enExample)
KR (1) KR101870589B1 (enExample)
CN (2) CN110343118A (enExample)
AU (1) AU2015308438B2 (enExample)
CA (1) CA2956191C (enExample)
CY (1) CY1121352T1 (enExample)
DK (1) DK3186257T3 (enExample)
ES (1) ES2714073T3 (enExample)
HR (1) HRP20190343T1 (enExample)
HU (1) HUE041941T2 (enExample)
IL (1) IL250287B (enExample)
LT (1) LT3186257T (enExample)
MA (3) MA48048A (enExample)
ME (1) ME03339B (enExample)
MX (1) MX369643B (enExample)
NZ (1) NZ728853A (enExample)
PL (1) PL3186257T3 (enExample)
PT (1) PT3186257T (enExample)
RS (1) RS58592B1 (enExample)
RU (1) RU2672569C2 (enExample)
SI (1) SI3186257T1 (enExample)
SM (1) SMT201900152T1 (enExample)
TR (1) TR201903332T4 (enExample)
WO (1) WO2016030444A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190343T1 (hr) * 2014-08-27 2019-05-31 Prexton Therapeutics Sa Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata
US10532057B2 (en) * 2015-08-27 2020-01-14 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
US20220089609A1 (en) 2018-07-26 2022-03-24 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
WO2007011701A1 (en) 2005-07-15 2007-01-25 Transform Pharmaceuticals, Inc. Novel hydrochloride salts of levodopa
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
EP2181110A2 (en) 2007-07-13 2010-05-05 ADDEX Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
EP2493871B1 (en) * 2009-10-30 2014-09-03 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
NZ767139A (en) * 2009-12-04 2022-08-26 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
US20140349994A1 (en) * 2012-01-18 2014-11-27 Addex Pharma S.A. Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors
HRP20190343T1 (hr) 2014-08-27 2019-05-31 Prexton Therapeutics Sa Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata
US10532057B2 (en) 2015-08-27 2020-01-14 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia

Similar Documents

Publication Publication Date Title
JP2019524822A5 (enExample)
JP2016535786A5 (enExample)
EP3043785B1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
RU2009126742A (ru) Композиции и способы применения (r)-прамипексола
JP2016528301A5 (enExample)
PH12020550631A1 (en) New catecholamine prodrugs for use in the treatment of parkinson`s disease
JP2013526544A5 (enExample)
HRP20191055T1 (hr) Terapeutska sredstva za neurodegenerativne bolesti
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
NZ700374A (en) New therapeutic approaches for treating parkinson’s disease
EA200800430A1 (ru) Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
JP2018507886A5 (enExample)
JP2012523430A5 (enExample)
JP2017525776A5 (enExample)
CA2864606C (en) Methods of treating and preventing diseases and disorders of the central nervous system
NI201800031A (es) Derivados de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
AR112683A1 (es) Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende
JP2020526591A5 (enExample)
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
JP2018502163A5 (enExample)
JP2015534990A5 (enExample)